Development finance ‘paramount’ in fight against AMR pandemic

  05 June 2021

In recent decades, the biological phenomenon known as antimicrobial resistance (AMR) – when bacteria, viruses, fungi and parasites become resistant to existing medicines – has resulted in the majority of our antimicrobial therapies becoming obsolete, leaving the world’s population susceptible to an ever-increasing range of infections. As a result, the possibility of a bacterial pandemic is today widely recognised as an imminent threat.

In a bid to combat the issue, the European Investment Bank (EIB) and BioVersys, a Swiss clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, last month signed a €20 million ($24.4 million) venture debt transaction. The financing supports the company’s research and development of a diverse pipeline of drugs that address AMR.

Further reading: TXF
Author(s): Oliver Gordon
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin